Dr. David Maloney is a world renowned expert on Rituxan (Rituximab) and a hematologist/oncologist and associate member of the clinical research division at the Fred Hutchinson Cancer Research Center in Seattle. He joins Andrew for this program to give us insights into the effectiveness of Rituximab therapy and discusses new and upcoming treatments for the lymphomas.
Dr. Maloney describes Rituximab, what it’s used for and how it’s being used in combination with chemotherapy and as a maintenance therapy. He also explains Rituximab resistance and what alternatives are available if Rituximab stops working. Dr. Maloney discusses why he’s excited about current research and what new antibodies are being developed that show promise for the future of lymphoma. You’ll also hear about the role of autologous stem cell transplants, allogenic stem cell transplants, and how each can affect your current treatment.
This program is a comprehensive overview of lymphoma treatment, addressing many questions that patients should be asking their doctor about new therapies, and exploring whether a clinical trial would be right for them. The future of lymphoma treatment is very bright and rapidly changing, and Dr. Maloney tells us what he is excited about in research for treating patients with lymphoma.
David Maloney, M.D., Ph.D.
Oncologist and Associate Member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care AllianceDr. Maloney is Associate Professor of Medicine at University of Washington’s oncology division, as well as an associate member of clinical research at the Fred Hutchinson Cancer Research Center. He has authored and co-authored articles for publication in The New England Journal of Medicine. Dr. Maloney received his medical degree and his doctorate in cancer biology from Stanford University, and... more >